

SYNTHESIS OF 2-ARYL-2H-INDAZOLES VIA COPPER(I)-CATALYZED INTRAMOLECULAR AMINATION REACTION

Rui Liu,^a Yong-ming Zhu,^{*a} Lie-na Qin,^a Shun-jun Ji,^a and Hajime Katayama^b

^aCollege of Pharmacy, Soochow University, Suzhou 215123, P. R. China
zhuyongming@suda.edu.cn

^bSchool of Pharmacy, Kinjo Gakuin University 2-1723, Ohmori, Moriyama-ku, Nagoya-city, Aichi, Posta code 463-8521, Japan

Abstract –A versatile method for the preparation of 2-aryl-2H-indazoles was developed by copper(I)-catalyzed intramolecular amination reaction under the conditions of [CuI/Cs₂CO₃(250 mol%)/1,4-dioxane/105 °C] starting from *N'*-aryl-*N'*-(*o*-bromobenzyl)acetylhydrazines. The method was applied to a wide scope of substrates and afforded indazole products in high yields.


INTRODUCTION

The indazole is an important subunit in drugs with high biological activities such as antitumor, anti-HIV, antidepressant, and contraceptive activities.¹⁻⁶ Despite of the importance of indazoles, the invention of general and efficient methods for the synthesis of fixed *N*-substituted indazoles has met with limited success, although the synthesis of *N*-aryl indazoles via a palladium-catalyzed intramolecular reaction has presented some valuable results.⁷ Here we wish to describe a novel method for the synthesis of 2-aryl-2H-indazoles via the copper(I)-catalyzed intramolecular reaction of *N'*-aryl-*N'*-(*o*-bromobenzyl)-acetylhydrazines.

RESULTS AND DISCUSSION

Our synthetic pathway is depicted in Scheme 1.

Scheme 1.



The starting material **1** was prepared from 2-bromobenzaldehydes by a modification of literature procedure.⁸ The following cyclization reaction was investigated using copper(I) iodide as catalyst. Basing upon Buchwald method,⁹ CuI was used for the intramolecular amination of **1a** (R₁,R₂=H), but no desired product **3a** (R₁,R₂=H) was obtained. In investigation of the experimental processes, we found that **1a** was found to be unstable in the reaction conditions, so we switched to use **2a** (R₁,R₂=H), available by acetylation of **1a**, as a starting material for cyclization.¹⁰ This pathway provided the cyclization product **4a** (R₁,R₂=H) in high yield. The results are summarized in Table 1. Weaker base such as K₂CO₃ provided better yields than Cs₂CO₃. Strong base such as *t*-BuONa may induce side reactions with poor yield. Brief

Table1. Optimization of reaction conditions in copper(I)-catalyzed intramolecular amination of **2a** (R₁=H, R₂=H)^a

| Solvent | Cu | Ligand | Base | Yield(%) ^b |
|---------|----------|---------------------|---------------------------------|-----------------------|
| dioxane | CuI | 1,10-phenanthroline | K ₂ CO ₃ | 93 |
| dioxane | CuI | 1,10-phenanthroline | Cs ₂ CO ₃ | 86 |
| dioxane | CuI | 1,10-phenanthroline | <i>t</i> -BuONa | 25 |
| dioxane | CuI | ethylenediamine | K ₂ CO ₃ | 63 |
| dioxane | CuBr | 1,10-phenanthroline | K ₂ CO ₃ | 80 |
| dioxane | no metal | 1,10-phenanthroline | K ₂ CO ₃ | 20 |
| toluene | CuI | 1,10-phenanthroline | K ₂ CO ₃ | 85 |
| dioxane | CuI | no ligand | K ₂ CO ₃ | 42 |
| dioxane | CuI | no ligand | Cs ₂ CO ₃ | 95 |
| dioxane | CuI | no ligand | <i>t</i> -BuONa | 20 |
| dioxane | CuBr | no ligand | Cs ₂ CO ₃ | 83 |
| dioxane | no metal | no ligand | Cs ₂ CO ₃ | <10 |


^aReaction was carried out in a pressure tube. A solution of **2a**, CuI, ligand and base in anhydrous solvent was heated at 100-105 °C for 20h. Cyclization product **4a** was obtained by chromatography.

^bIsolated yields after chromatography.

studies of the effect of ligand addition was also carried out. Employment of 1,10-phenanthroline as a ligand in combination with K₂CO₃ yielded good result, but replacement with ethylenediamine resulted in a decrease in yields. It was also noted that the use of CuBr as catalyst slightly lowered the yield. Reaction without copper(I) catalyst led to drop the yield markedly. Anhydrous 1,4-dioxane was used as solvent affording better yield than toluene with better solubility of **2a**. When **2a** was subjected to the conditions of CuI/1,10-phenanthroline/K₂CO₃ at 100-105 °C for 20h in anhydrous 1,4-dioxane, **4a** was obtained in

93% yield. Reaction without ligand by CuI/K₂CO₃ at 100-105 °C for 20h produced **4a** in low yield 42%, but prolonged heating for 30h improved the yield up to 93%. So unnecessary of the ligand in mind, we looked into the influence of bases in reaction outcome (Table 1). The best results with 95% yield was obtained by the reaction conditions with CuI/Cs₂CO₃ at 100-105 °C for 20h in anhydrous 1,4-dioxane.

Table 2. Copper(I)-catalyzed Intramolecular amination reaction for synthesis 2-aryl-2*H*-indazoles



| Entry | 2 | | 4 | | Yield (%) ^a | Yield (%) ^b | 5 | | Yield (%) ^c |
|-------|------------------|--------------------|------------------|--------------------|------------------------|------------------------|------------------|--------------------|------------------------|
| | R ₁ , | R ₂ | R ₁ , | R ₂ | | | R ₁ , | R ₂ | |
| 1 | H, | H(2a) | H, | H(2a) | 93 | 95 | H, | H(2a) | 94 |
| 2 | H, | 4'-Me | H, | 4'-Me | 92 | 92 | H, | 4'-Me | 99 |
| 3 | H, | 4'-OMe | H, | 4'-OMe | 93 | 96 | H, | 4'-OMe | 98 |
| 4 | H, | 3'-CF ₃ | H, | 3'-CF ₃ | 80 | 91 | H, | 3'-CF ₃ | 91 |
| 5 | H, | 4'-F | H, | 4'-F | 94 | 98 | H, | 4'-F | 87 |
| 6 | H, | 3'-CN | H, | 3'-CN | 87 | 87 | H, | 3'-CN | 81 |
| 7 | H, | 4'-Cl | H, | 4'-Cl | 88 | 95 | H, | 4'-Cl | 95 |
| 8 | 5-F, | H | 5-F, | H | 87 | 89 | 5-F, | H | 91 |
| 9 | 5-OMe, | H | 5-OMe, | H | 85 | 85 | 5-OMe, | H | 90 |

^a**2a** was subjected to the reaction conditions of CuI/1,10-phenanthroline/K₂CO₃ at 100-105 °C for 20h in anhydrous 1,4-dioxane. Isolated yields were obtained after chromatography.

^b**2a** was subjected to the reaction conditions of CuI/Cs₂CO₃ at 100-105 °C for 20h in anhydrous 1,4-dioxane. Isolated yields were obtained after chromatography.

^cIsolated yields were obtained after chromatography.

Hydrolysis of *N*-acetyl compound **4a** was effected with sodium hydroxide in aqueous methanol at 70 °C under a nitrogen atmosphere. Work-up of the reaction mixture with ice and extraction with dichloromethane gave NH product **3a** in good yield. Since the NH product was unstable, and prone to air oxidation, hydrolysis of **4a** and subsequent oxidation of the product **3a** generated indazole **5a** (R₁,R₂=H) in good yield. Thus, the general method for the synthesis of a variety of 2-aryl-2*H*-indazoles via copper(I)-catalyzed intramolecular amination reaction was established, and the result is summarized in Table 2. Since methoxy, trifluoromethyl, cyano, methyl, chloro, and fluoro groups were all tolerated

under these reaction conditions, so we found these reaction conditions were equally effective for both electron-rich and electron-deficient substrates.

In summary, we are able to develop a new method for the synthesis of 2-aryl-2*H*-indazoles **5** in high yields starting from *N'*-aryl-*N'*-(*o*-bromobenzyl)acetylhydrazines **2**, which are readily prepared by a modification of literature procedure. Intramolecular C-N bond formation catalyzed by copper(I) iodide without ligand was used to transfer **2** to **4** as a key reaction. This method was simple, economical, and applicable to a wide scope of substrates affording indazole derivatives in high yields. The progress along this line of research will be reported in due course.

EXPERIMENTAL

General procedure for the preparation of **2** from **1**:

The solution of **1** (2 mmol) and Ac₂O (2 mmol) in CH₂Cl₂ (10 mL) was stirred at rt overnight. The solution was washed with water and dried over anhydrous sodium sulfate. After removing the solvent, residue was purified by chromatography on silica gel with petroleum EtOAc to afford white solid **2**.

General Procedure for the synthesis of **4** from **2**:

N'-Aryl-*N'*-(*o*-bromobenzyl)acetylhydrazine (1.0 mmol) **2**, anhydrous 1,4-dioxane (2.5 mL), CuI (10 mg, 0.05 mmol), 1,10-phenanthroline (18 mg, 0.1 mmol) / no ligand, and K₂CO₃ (345 mg, 2.5 mmol) / Cs₂CO₃ (814 mg, 2.5 mmol) were placed in a pressure tube, and the tube was sealed after filling with N₂. Reaction was initiated by heating, and temperature was kept at 100-105 °C for 20h. Solution was filtered through Celite pad, and the filtrate was evaporated. Chromatography (silica gel, petroleum EtOAc) gave **4** as white crystals.

General Procedure for the synthesis of **5**:

To the solution of **4** (0.5 mmol) in MeOH (6 mL) was added 5mol/L NaOH (1.5 mL), and the mixture was heated to 70 °C for 30min while protected with N₂. The reaction mixture was poured into ice-water (20 g), and suspension was extracted with CH₂Cl₂ (40+20 mL). The collected solution was washed with water (30 mL×2) and dried over sodium sulfate. This solution was left stirring at rt overnight to complete air oxidation. After filtration, the filtrate was concentrated and the residual material was purified by chromatography on silica gel with petroleum EtOAc to afford **5** as solid.

***N'*-Phenyl-*N'*-(*o*-bromobenzyl)acetylhydrazine (2a):** white crystals (EtOAc), mp 76.7~77.9 °C. ¹H NMR (400MHz, CDCl₃): δ 1.82 (1H, s), 2.00 (1H, s), 4.49 (1H, d, *J*=15.2 Hz), 4.82 (1H, s), 4.90 (1H, d, *J*=15.2 Hz), 6.82~6.90 (3H, m), 7.01 (3H, t, *J*=8.4 Hz), 7.17~7.28 (7H, m), 7.34 (2H, t, *J*=8.8 Hz), 7.44 (1H, d, *J*=7.6 Hz), 7.61 (2H, q, *J*=8.0 Hz). ¹³C NMR (400MHz, CDCl₃): 19.49, 21.29, 59.75, 57.79, 113.15, 114.68, 120.26, 121.87, 128.05, 128.13, 129.49, 129.72, 130.02, 130.08, 130.34, 131.39, 133.36, 133.69, 135.19, 136.59, 149.41, 148.64, 169.64. IR: 3170, 2930, 2866, 1676, 1630, 1497, 753, 693.

HRMS: calcd for C₁₅H₁₅N₂OBr: 320.0347, found: 320.0275.

1-Acetyl-2-phenyldihydroindazole (4a): white crystals (EtOAc), mp 80~81.8 °C. ¹H NMR (400MHz, CDCl₃): δ 2.21 (3H, s), 4.56 (1H, d, *J*=11.8 Hz), 4.95 (1H, d, *J*=12.5 Hz), 7.03~7.06 (3H, m), 7.11~7.15 (2H, m), 7.27~7.29 (3H, m), 8.01 (1H, d, *J*=8.0 Hz). ¹³C NMR (400MHz, CDCl₃): 22.55, 61.52, 117.67, 122.94, 123.85, 125.50, 128.43, 128.90, 129.70, 139.90, 152.74, 171,17. IR: 2924, 2871, 1669, 1591, 1475, 757, 699. HRMS: calcd for C₁₅H₁₄N₂O: 238.1106, found: 238.1102.

***N'*-(4-methylphenyl)-*N'*-(*o*-bromobenzyl)acetylhydrazine:** white crystals (EtOAc), mp 161.6~163.1 °C. ¹H NMR (400MHz, CDCl₃): δ 1.80 (3H, s), 1.97 (3H, s), 2.25 (3H, s), 2.32 (3H, s), 4.40 (1H, d, *J*=14.8 Hz), 4.78 (2H, s), 4.86 (1H, d, *J*=14.4 Hz), 6.79 (1H, d, *J*=8.0 Hz), 6.92 (3H, t, *J*=8.4 Hz), 7.05 (1H, d, *J*=8.0 Hz), 7.12~7.29 (m, 8H), 7.46 (1H, d, *J*=7.6 Hz), 7.61 (2H, q, *J*=8.8 Hz). ¹³C NMR (400MHz, CDCl₃): 19.44, 20.73, 20.80, 21.26, 57.96, 60.12, 113.38, 115.04, 123.78, 124.94, 127.94, 128.00, 129.32, 129.47, 129.95, 130.14, 130.37, 130.42, 131.41, 131.60, 133.20, 133.54, 135.35, 136.75, 146.48, 147.27, 176.59. IR: 3162, 2915, 2864, 1677, 1627, 1513, 1449, 807, 746. HRMS: calcd for C₁₆H₁₇N₂OBr: 334.0504, found: 334.0515.

1-Acetyl-2-(4-methylphenyl)dihydroindazole: white crystals (EtOAc), mp 106.9~107.5 °C. ¹H NMR (400MHz, CDCl₃): δ 2.20 (3H, s), 2.33 (1H, s), 4.50 (1H, d, *J*=6.8 Hz), 4.92 (1H, d, *J*=10.8 Hz), 6.94 (2H, d, *J*=8.4 Hz), 7.07~7.14 (4H, m), 7.30 (1H, t, *J*=6.8 Hz), 8.01 (1H, d, *J*=8.0 Hz). ¹³C NMR (400MHz, CDCl₃): 20.95, 22.58, 61.73, 117.36, 117.79, 123.01, 123.05, 125.45, 128.42, 128.95, 130.24, 133.50, 139.97, 150.41, 171.09. IR: 2921, 2865, 1673, 1599, 1506, 814, 758. HRMS: calcd for C₁₆H₁₆N₂O: 252.1263, found: 252.1271.

***N'*-(4-Methoxyphenyl)-*N'*-(*o*-bromobenzyl)acetylhydrazine:** white crystals (EtOAc), mp 137.0~138.5 °C. ¹H NMR (400MHz, CDCl₃): δ 1.79 (3H, s), 1.96 (3H, s), 3.75(2H, s), 3.79 (3H, s), 4.76 (2H, s), 6.83~7.00 (5H, m), 7.02 (2H, d, *J*=2.4 Hz), 7.17~7.22 (2H, m), 7.26~7.27 (4H, m), 7.38 (1H, d, *J*=7.6 Hz), 7.61 (1H, t, *J*=8.0 Hz). ¹³C NMR (400MHz, CDCl₃): 19.54, 21.40, 56.02, 56.07, 58.38, 61.24, 115.10, 115.18, 115.27, 117.37, 123.93, 125.21, 128.01, 129.40, 130.04, 130.62, 132.05, 133.24, 133.56, 135.48, 136.78, 143.03, 143.70, 154.21, 155.53, 169.71, 176.52. IR: 3183, 2947, 2903, 2829, 1678, 1635, 1509, 816, 753. HRMS: calcd for C₁₆H₁₇N₂O₂Br: 350.0453, found: 350.0469.

1-Acetyl-2-(4-methoxyphenyl)dihydroindazole: white crystals (EtOAc), mp 117.9~118.6 °C. ¹H NMR (400MHz, CDCl₃): δ 2.20 (3H, s), 3.76 (3H, s), 4.40 (1H, d, *J*=6.8 Hz), 4.89 (1H, d, *J*=7.6 Hz), 6.29 (2H, d, *J*=5.6 Hz), 6.98~7.15 (4H, m), 7.329 (1H, t, *J*=2.0 Hz), 8.02 (1H, d, *J*=8.0 Hz). ¹³C NMR (400MHz, CDCl₃): 22.67, 55.91, 62.07, 114.99, 117.24, 119.47, 123.15, 125.46, 128.48, 128.86, 140.08, 146.22, 156.64, 170.93. IR: 2908, 2831, 1671, 1602, 1501, 835, 745. HRMS: calcd for C₁₆H₁₆N₂O₂: 268.1212, found: 268.1213.

***N'*-(3-Trifluoromethylphenyl)-*N'*-(*o*-bromobenzyl)acetylhydrazine:** white crystals (EtOAc), mp

117.6~118.8 °C. ¹H NMR (400MHz, CDCl₃): δ 1.81 (1H, s), 1.99 (3H, s), 4.59 (1H, d, *J*=14.4 Hz), 4.89 (2H, s), 4.90 (1H, d, *J*=14.4 Hz), 6.82 (1H, s), 6.98 (2H, d, *J*=8.4 Hz), 7.10 (2H, t, *J*=8.0 Hz), 7.31~7.18 (8H, m), 7.34 (1H, t, *J*=8.4 Hz), 7.61 (1H, t, *J*=8.4 Hz). ¹³C NMR (400MHz, CDCl₃): 21.25, 57.28, 59.49, 109.49, 109.54, 111.04, 115.99, 116.68, 116.72, 117.58, 118.34, 118.36, 124.10, 128.15, 128.29, 129.91, 130.28, 130.42, 130.66, 130.46, 131.40, 132.90, 133.58, 133.85, 134.33, 135.71, 148.96, 149.68, 169.80. IR: 3260, 2999, 2360, 1672, 1614, 1508, 783, 748, 698. HRMS: calcd for C₁₆H₁₄N₂OF₃Br: 386.0242, found: 386.0245.

1-Acetyl-2-(3-trifluoromethylphenyl)dihydroindazole: white crystals (EtOAc), mp 139.0~140.6 °C. ¹H NMR (400MHz, CDCl₃): δ 2.21 (3H, s), 4.58 (1H, d, *J*=14.6 Hz), 5.03 (1H, d, *J*=13.3 Hz), 7.13~7.19 (2H, m), 7.24 (1H, d, *J*=8.0 Hz), 7.28~7.36 (3H, m), 7.41 (1H, t, *J*=7.6 Hz), 7.99 (1H, d, *J*=8 Hz). ¹³C NMR (400MHz, CDCl₃): 22.53, 61.52, 114.58, 114.61, 117.88, 120.48, 122.98, 125.93, 128.50, 128.75, 130.41, 132.24, 139.68, 153.37, 171.52. IR: 2925, 2360, 1686, 1610, 1476, 793, 769, 697. HRMS: calcd for C₁₆H₁₃N₂OF₃: 306.0980, found: 306.0982.

***N'*-(4-Fluorophenyl)-*N'*-(*o*-bromobenzyl)acetylhydrazine:** white crystals (EtOAc), mp 139.0~140.5 °C. ¹H NMR (400MHz, CDCl₃): δ 1.80 (3H, s), 1.97 (3H, s), 4.39 (1H, d, *J*=14.4 Hz), 4.77 (2H, s), 4.93 (1H, d, *J*=14.4 Hz), 6.78 (2H, q, *J*=4.4 Hz), 6.81~7.06 (5H, m), 7.16~7.30 (6H, m), 7.43 (1H, d, *J*=8 Hz), 7.61 (2H, q, *J*=3.6 Hz). ¹³C NMR (400MHz, CDCl₃): 19.50, 21.32, 58.17, 60.89, 114.59, 114.67, 116.00, 116.23, 116.35, 116.57, 116.90, 116.98, 123.90, 125.11, 128.04, 128.10, 129.60, 130.23, 130.37, 131.87, 133.37, 133.65, 134.99, 136.30, 145.09, 145.93, 157.41, 156.36, 169.92, 176.84. IR: 3278, 2999, 1667, 1503, 1450, 818, 748. HRMS: calcd for C₁₅H₁₄N₂OFBr: 336.0274, found: 336.0260.

1-Acetyl-2-(4-fluorophenyl)dihydroindazole: white crystals (EtOAc), mp 111.6~112.9 °C. ¹H NMR (400MHz, CDCl₃): δ 2.19 (3H, s), 4.45 (1H, d, *J*=11.2 Hz), 4.94 (1H, d, *J*=10.8 Hz), 6.95~7.03 (4H, m), 7.11~7.16 (2H, m), 7.33 (1H, t, *J*=7.6 Hz), 8.00 (1H, d, *J*=8.0 Hz). ¹³C NMR (400MHz, CDCl₃): 22.65, 62.00, 116.29, 116.52, 117.43, 119.40, 119.48, 123.13, 125.71, 128.63, 139.76, 148.85, 172.68. IR: 2916, 1672, 1603, 1501, 854, 749. HRMS: calcd for C₁₅H₁₃N₂OF: 256.1012, found: 256.1018.

***N'*-(3-Cyanophenyl)-*N'*-(*o*-bromobenzyl)acetylhydrazine:** white crystals (EtOAc), mp 179.8~180.8 °C. ¹H NMR (400MHz, CDCl₃): δ 1.81 (3H, s), 2.00 (3H, s), 4.58 (1H, d, *J*=15.2 Hz), 4.81 (2H, s), 4.89 (1H, d, *J*=15.2 Hz), 6.88 (1H, s), 7.02 (2H, d, *J*=0.8 Hz), 7.041 (2H, s), 7.05~7.31 (9H, m), 7.33 (2H, t, *J*=8.0 Hz), 7.61 (2H, t, *J*=8.0 Hz). ¹³C NMR (400MHz, CDCl₃): 21.26, 57.29, 59.25, 113.49, 115.95, 117.14, 118.54, 119.68, 120.30, 123.45, 124.01, 125.06, 128.18, 130.03, 130.24, 130.58, 130.98, 131.16, 133.66, 133.92, 133.94, 135.34, 140.04, 149.07, 150.39, 155.92, 169.77. IR: 3238, 2815, 2224, 1675, 1601, 1492, 782, 748, 679. HRMS: calcd for C₁₆H₁₄N₃OBr: 345.0300, found: 345.0304.

1-Acetyl-2-(3-cyanophenyl)dihydroindazole: white crystals (EtOAc), mp 160.6~161.8 °C. ¹H NMR (400MHz, CDCl₃): δ 2.20 (3H, s), 4.54 (1H, d, *J*=12.4 Hz), 5.02 (1H, d, *J*=12.4 Hz), 7.14~7.18 (2H, m),

7.30~7.36 (4H, m), 7.41 (1H, t, $J=7.6$ Hz), 7.97 (1H, d, $J=8.0$ Hz). ^{13}C NMR (400MHz, CDCl_3): 22.56, 61.42, 113.88, 117.94, 118.89, 120.84, 121.94, 122.99, 126.08, 127.41, 128.24, 128.86, 130.78, 139.44, 153.45, 171.44. IR: 2924, 2229, 1681, 1476, 1380, 795, 767, 666. HRMS: calcd for $\text{C}_{16}\text{H}_{13}\text{N}_3\text{O}$: 263.1059, found: 263.1060.

2-(3-Cyanophenyl)-2H-indazole: white crystals (EtOAc), mp 210.2~211.5 °C. ^1H NMR (400MHz, DMSO): 7.14 (1H, t, $J=7.6$ Hz), 7.35 (1H, t, $J=7.2$ Hz), 7.68~7.75 (2H, m), 7.81 (1H, dd, $J=8.0, 8.0$ Hz), 7.94 (1H, d, $J=7.6$ Hz), 8.25 (1H, d, $J=7.6$ Hz), 8.57 (1H, s), 9.16 (1H, s). ^{13}C NMR (400MHz, CDCl_3): 30.87, 117.62, 119.47, 121.24, 122.04, 122.51, 122.72, 123.08, 126.93, 127.30, 130.06, 135.87, 140.11, 149.27. IR: 1666, 1628, 1584, 1480, 781, 753, 681. HRMS: calcd for $\text{C}_{14}\text{H}_9\text{N}_3$: 218.0955, found: 218.0957.

***N'*-(4-Chlorophenyl)-*N'*-(*o*-bromobenzyl)acetylhydrazine:** white crystals (EtOAc), mp 161.8~162.2 °C. ^1H NMR (400MHz, CDCl_3): δ 1.77 (3H, s), 1.98 (3H, s), 4.49 (1H, d, $J=15.2$ Hz), 4.85 (1H, d, $J=15.6$ Hz), 4.78 (2H, s), 6.75 (2H, d, $J=8.8$ Hz), 6.94 (2H, t, $J=8.8$ Hz), 7.16~7.21 (9H, m), 7.39 (1H, d, $J=7.2$ Hz), 7.61 (2H, t, $J=9.6$ Hz). ^{13}C NMR (400MHz, CDCl_3): 19.42, 21.19, 57.74, 59.80, 114.35, 116.00, 123.81, 124.86, 125.01, 126.92, 128.01, 128.11, 129.47, 129.61, 129.83, 130.20, 130.22, 131.37, 133.39, 133.67, 134.73, 136.08, 147.29, 147.99, 169.72, 176.54. IR: 3158, 2931, 1676, 1626, 1492, 818, 750. HRMS: calcd for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{OClBr}$ ($\text{M}-\text{C}_2\text{H}_4\text{ON}$): 294.0686, found: 294.0694.

1-Acetyl-2-(4-chlorophenyl)dihydroindazole: white crystals (EtOAc), mp 109.1~110.5 °C. ^1H NMR (400MHz, CDCl_3): δ 2.19 (3H, s), 4.49 (1H, d, $J=10.4$ Hz), 4.94 (1H, d, $J=11.6$ Hz), 6.99 (2H, d, $J=9.2$ Hz), 7.13~7.23 (3H, m), 7.26 (1H, d, $J=2.0$ Hz), 7.32 (1H, t, $J=8.0$ Hz), 7.98 (1H, d, $J=8.0$ Hz). ^{13}C NMR (400MHz, CDCl_3): 22.59, 61.63, 117.57, 119.06, 123.03, 125.76, 128.64, 129.04, 129.75, 139.65, 151.36, 171.25. IR: 2932, 2865, 1668, 1589, 1476, 844, 760. HRMS: calcd for $\text{C}_{15}\text{H}_{13}\text{N}_2\text{OCl}$: 274.0687, found: 274.0700.

***N'*-(2-Bromo-5-fluorobenzyl)-*N'*-phenylacetylhydrazine:** white crystals (EtOAc), mp 180.4~182.0 °C. ^1H NMR (400MHz, CDCl_3): δ 1.91 (3H, s), 2.04 (3H, s), 4.53 (1H, d, $J=15.6$ Hz), 4.77 (2H, s), 4.99 (1H, d, $J=14.2$ Hz), 6.77 (3H, d, $J=8.0$ Hz), 6.86~6.91 (3H, m), 6.94~7.02 (6H, m), 7.26~7.35 (4H, m), 7.52~7.59 (2H, m). ^{13}C NMR (400MHz, CDCl_3): 19.71, 21.36, 58.39, 59.79, 112.94, 114.49, 116.36, 116.56, 116.82, 117.06, 117.18, 117.27, 117.94, 118.45, 120.44, 122.07, 128.24, 128.65, 129.79, 130.19, 134.27, 134.50, 134.91, 142.92, 148.18, 148.91, 171.37, 176.65. IR: 3159, 2924, 2851, 1664, 1595, 1499, 887, 808, 700. HRMS: calcd for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{OFBr}$ ($\text{M}-\text{C}_2\text{H}_4\text{ON}$): 279.9960, found: 279.9987.

5-Fluoro-1-acetyl-2-phenyldihydroindazole: white crystals (EtOAc), mp 50.3~51.7 °C. ^1H NMR (400MHz, CDCl_3): δ 2.19 (3H, s), 4.52 (1H, d, $J=10.8$ Hz), 4.96 (1H, d, $J=27.2$ Hz), 6.95 (1H, d, $J=6.4$ Hz), 7.00~7.07 (3H, m), 7.26~7.36 (3H, m), 7.95 (1H, dd, $J=8.0, 8.0$ Hz). ^{13}C NMR (400MHz, CDCl_3): 22.43, 61.39, 110.46, 110.71, 114.90, 115.13, 117.62, 118.51, 121.37, 124.14, 128.26, 128.65, 129.85,

130.19. IR: 2916, 2847, 1653, 1589, 1483, 882, 810, 699. HRMS: calcd for C₁₅H₁₃N₂O₂F: 256.1012, found: 256.1008.

5-Fluoro-2-phenyl-2H-indazole: white crystals (EtOAc), mp 109.7~110.8 °C. ¹H NMR (400MHz, CDCl₃): δ 7.13 (2H, q, *J*=6.8 Hz), 7.42 (1H, t, *J*=6.8 Hz), 7.54 (2H, t, *J*=8.0 Hz), 7.77 (1H, q, *J*=4.2 Hz), 7.89 (2H, d, *J*=8.0 Hz), 8.38 (1H, s). ¹³C NMR (400MHz, CDCl₃): 118.80, 119.09, 120.42, 120.52, 120.91, 121.00, 121.29, 128.24, 128.24, 128.50, 128.60, 130.05, 130.16, 140.78. IR: 1664, 1595, 1523, 1500, 854, 812, 752, 682. HRMS: calcd for C₁₃H₉N₂F: 212.0750, found: 212.0742.

N²-(2-Bromo-5-methoxyphenyl)-N¹-phenylacetylhydrazine: white crystals (EtOAc), mp 121.5~122.3 °C. ¹H NMR (400MHz, CDCl₃): δ 1.94 (6H, bt, *J*=30.4 Hz), 3.73 (6H, bt, *J*=10 Hz), 4.76 (1H, s), 4.83 (1H, d, *J*=15.2 Hz), 4.97 (1H, d, *J*=15.2 Hz), 5.00 (1H, s), 6.65~6.94 (6H, m), 7.01 (2H, d, *J*=8.0 Hz), 7.04~7.13 (2H, m), 7.33 (4H, bt, *J*=7.6 Hz), 7.48 (2H, q, *J*=8.8 Hz). ¹³C NMR (400MHz, CDCl₃): 23.13, 25.27, 52.96, 55.95, 58.24, 59.79, 113.18, 113.21, 114.52, 114.92, 115.25, 115.33, 115.40, 115.43, 116.24, 117.14, 120.44, 121.88, 128.49, 129.78, 130.09, 133.67, 133.89, 134.29, 148.62, 171.54, 172.28. IR: 3184, 2932, 1680, 1630, 1595, 1473, 872, 807, 755, 696. HRMS: calcd for C₁₆H₁₇N₂O₂Br (M-C₂H₄ON): 290.0181, found: 290.0184.

5-Methoxy-1-acetyl-2-phenyldihydroindazole: white crystals (EtOAc), mp 99.9~101.3 °C. ¹H NMR (400MHz, CDCl₃): δ 2.18 (3H, s), 3.77 (3H, s), 4.49 (1H, d, *J*=13.2 Hz), 4.94 (1H, d, *J*=9.6 Hz), 6.70 (1H, s), 6.83 (1H, d, *J*=8.8 Hz), 7.04 (2H, d, *J*=8.0 Hz), 7.26~7.30 (3H, m), 7.90 (1H, d, *J*=8.8 Hz). ¹³C NMR (400MHz, CDCl₃): 23.13, 25.27, 52.96, 55.95, 58.24, 59.79, 113.17, 113.21, 114.52, 114.92, 115.33, 115.33, 115.39, 115.43, 116.24, 117.14, 120.44, 121.88, 128.49, 129.78, 130.09, 133.67, 133.90, 134.29, 148.62, 171.54, 172.28. IR: 2926, 2847, 1664, 1600, 1482, 1394, 869, 811, 772, 700. HRMS: calcd for C₁₆H₁₆N₂O₂: 268.1212, found: 268.1205.

ACKNOWLEDGEMENTS

This work was partially supported by the National Natural Science Foundation of China (Grants 20472062 and 20672079), and Natural Science Foundation of Jiangsu Province (No BK2006048).

REFERENCES

1. J. Elguero, In *Comprehensive Heterocyclic Chemistry*; ed. by A. R. Katritzky and C. W. Rees; Pergamon Press: New York, 1984, Vol. **5**, p. 167.
2. (a) G. A. Bistochi, G. De Meo, M. Pedini, A. Ricci, H. Brouilhet, S. Bucherie, M. Rabaud, and P. Jacquignon, *Farmaco Ed. Sci.*, 1981, **36**, 315. (b) G. Picciola, F. Ravenna, G. Carenini, P. Gentili, and M. Riva, *Farmaco Ed. Sci.*, 1981, **36**, 1037.
3. B. K. Keppler and M. Hartmann, *Met.-Based Drugs*, 1994, **1**(2-3), 145.

4. (a) J.-H. Sun, C. A. Teleha, J.-S. Yan, J. D. Rodgers, and D. A. Nugiel, *J. Org. Chem.*, 1997, **62**, 5627. (b) J. D. Rodgers, B. L. Johnson, H. Wang, R. A. Greenberg, S. Erickson-Viitanen, R. M. Klabe, B. C. Cordova, M. M. Rayner, G. N. Lam, and C.-H. Chang, *BioMed. Chem. Lett.*, 1996, **6**, 2919.
5. Y. Ikeda, N. Takano, H. Matsushita, Y. Shiraki, T. Koide, R. Nagashima, Y. Fujimura, M. Shindo, S. Suzuki, and T. Iwasaki, *Arzneim.-Forsch.*, 1979, **29**, 511.
6. G. Corsi, G. Palazzo, C. Germani, P. S. Barcellona, and B. Silvestrini, *J. Med. Chem.*, 1976, **19**, 778.
7. J. J. Song and N. K. Yee, *Org. Lett.*, 2000, **2**, 519.
8. U. Lerch and J. Konig, *Synthesis*, 1983, 157.
9. A. Klapars, J. C. Antilla, X.-H. Huang, and S. L. Buchwald, *J. Am. Chem. Soc.*, 2001, **123**, 7727.
10. Y.-M. Zhu, Y. Kiryu, and H. Katayama, *Tetrahedron Lett.*, 2002, **43**, 3577.